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ABSTRACT 
Biosimilar medicines are biotherapeutics that are similar in quality, safety and efficacy to 
previously licensed reference biotherapeutics. The slightest change in any stage of production 
can cause differences in the product. Among the factors, affecting production can be listed as; 
host cell selection, fermenter type, ambient conditions, broth, substances used for cell culture, 
fermentation method and purification method. The similarity should be demonstrated by 
comparative quality, non-clinical and clinical tests. Research and development studies in the 
biopharmaceutical field bring diversity of quality control methods along with the formulation 
and manufacturing method of the biosimilars. Although there are some standardized and 
validated quality control methods given in the internationally recognized pharmacopoeias, 
there are many in house methods of biopharmaceutical product owners that can only be used 
as internal quality control methods by them. The main international sources for quality 
control methods of biopharmaceutics can be given as pharmacopoeias, International 
Organization for Standardization standards and Organization for Economic Co-operation and 
Development methods. In this review manufacturing process, regulatory guidelines and 
quality control of biosimilar medicines briefly are given. 
Keywords:Biosimilars, biotherapeutics, manufacturing, quality control, pharmacopoeial 
methods 
 
INTRODUCTION 
Biosimilar medicines are biotherapeutics that are similar in quality, safety and efficacy to 
previously licensed reference biotherapeutics (1). Since the exact production method of the 
reference biological product is not known, different processes are mostly used in the 
production of biosimilar drugs. The slightest change in any stage of production can cause 
differences in the product. Among the factors, affecting production can be listed as; host cell 
selection, fermenter type, ambient conditions, broth, substances used for cell culture, 
fermentation method and purification method (2). Good Manufacturing Practices-GMP 
requirements for biological and biosimilar products are higher than for small molecules. The 
similarity should be demonstrated by comparative quality, non-clinical and clinical tests 
(1,3). While non-clinical tests can be grouped as physicochemical characterization, biological 
characterization, pre-clinical and pharmacokinetic-PK/pharmacodynamic-PD tests, clinical 
tests can be grouped as PK-PD tests, all reliability and effectiveness studies and clinical 
studies. Biosimilar products have high degree of similarity to the reference products, but they 
are not accepted as bioequivalent products (4). Research and development studies in the 
biopharmaceutical field bring diversity of quality control methods along with the formulation 
and manufacturing method of the biosimilars under the biological/biotechnological 
medicines. Although there are some standardized and validated quality control methods given 
in the internationally recognized pharmacopoeias, there are many in house methods of 
biopharmaceutical product owners that can only be used as internal quality control methods 
by them. The main international sources for quality control methods of biopharmaceutics can 
be given as pharmacopoeias (5-9), International Organization for Standardization-ISO 
standards (10) and Organization for Economic Co-operation and Development-OECD 
methods (11).Between the pharmacopoeias European Pharmacopoeia, United States 
Pharmacopoeia, British Pharmacopoeia and Japanese Pharmacopoeia are mostly accepted 
ones. In the scope of above mentioned pharmacopoeias the analyses of biological and 
 biotechnological medicines can be grouped as physical, chemical, pharmacological and 
microbiological controls. Those include identity, quantity and potency tests, thermostability, 
viral control tests, total and bound protein and purity (impurity) controls, sterility test, 
bacterial endotoxin and pyrogenicity test to prove their efficacy and safety. In this review, 
biosimilar medicines are briefly overviewed in the scope of regulations, manufacturing and 
quality control methods take place in the international standards such as pharmacopoeias. 
 
 
Regulatory Guidelines for Biosimilars 
Regulatory guidelines for biosimilars released by European Medicines Agency-EMA (1), 
U.S. Food And Drug Administration-FDA (11) and World Health Organisation-WHO (12) 
are listed below. 
 
European Medicines Agency  
 Guidelines on Similar Biological Medicinal Products  
 Guideline on Similar Biological Medicinal Products Containing 
Biotechnology-Derived Proteins as Active Substance: Non-Clinical and 
Clinical Issues  
 Guideline on Similar Biological Medicinal Products Containing 
Biotechnology-Derived Proteins as Active Substances: Quality Issues 
 Questions and Answers on Biosimilar Medicines (Similar Biological 
Medicinal Products. 
 
 
U.S. Food And Drug Administration 
 Guidance for Industry: Scientific Considerations in Demonstrating 
Biosimilarity to a Reference Product 
 Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity 
to a Reference Product 
 Guidance for Industry: Clinical Pharmacology Data to Support a 
Demonstration of Biosimilarity to a Reference Product. 
 
World Health Organisation 
 Guidelines for Evaluation of Similar Biotherapeutic Products-SBPs. 
 
 
Manufacturing Process of Biosimilars 
 
Basic steps for manufacturing process of biosimilars are presented in Figure 1 and the critical 
factors for these steps are given below (2). 
 
Figure 1. Basic steps for manufacturing process of biosimilars. 
  
Critical factors that are effective on the success of the manufacturing steps are given below. 
 
Cell line selection 
• Mammalian 
• Bacteria 
• Yeast 
 
Cell culture process development
• Oxygen levels 
• Lactate production 
• Temperature 
• pH 
• Osmolality  
• Duration 
 
Purification process 
• Columnchromatography
• Filtration 
• Centrifugation 
 
Formulation 
• Buffer conditions  
• pH 
• Ionic strength 
• Excipients amounts 
• The final formulation (
 
 
Quality Control of Biosimilars
 
Under the class of biological and biotechnological medicines the biosimilars are analysed for 
below given tests and surveillance in terms to prove their quality
 
 
Characterization 
•Cell Line
•Cell Volume Expension
•Production Culture
•Centrifugation / Deep Filtration
•Chromatographic purification
•Virus filtration
•Consantration and formulation
 
 
 
liquid, frozen liquid or lyophilisate) 
 
 (13).  
 
 Characterization of biological and biotechnological medicines are evaluated according to the 
ICH Q6B guideline (14). 
o Physicochemical Properties 
 Composition determination 
 Physical determination 
 Primarly Structure determination 
 Heterogenity (activity, efficacy, safety) 
 
o Biological Activity 
 Biological Assay (animal based, cell culture based, biochemical assay) 
 Potency 
 
o Immunochemical proporties 
 Affinity 
 Avidity 
 Immunoreactivity 
 
o Puritiy, impurity, and contaminants 
 
o Quantity 
 
Stability 
The effect of temperature, humudity, accelarated and stress conditions, light, container/ 
closure system, stability after reconstitution of freeze-dried product variables on stability is 
evaluated in terms of the following parameters, which are indicated in the ICH Q5C guideline 
(15); 
 
 Potency 
 Purity and Molecular Characterisation 
 Other Caracteristics; 
o Visual appearance (colour and opacity for solutions/suspensions; colour, 
texture and dissolution time for powders) 
o Visible particulates (solutions or after the reconstitution of powders or 
lyophilised cakes) 
o pH,  
o Moisture level (powders and lyophilised products) 
o Sterility testing or alternatives (e.g., container/closure integrity testing) 
o Effect of additives (exipients, stabilisers, preservatives etc.)  have to been 
evaluated. 
o Effect of container closure systems should be evaluated 
 
Comparision Studies for Manufacturing Quality 
Comparability of biotechnological/biological products subject to changes in their 
manufacturing process are presented in ICH Q5E Guideline interms of non clinical and 
clinical studies (16). 
 Pharmacokinetic-PK 
 Pharmacodynamic-PD 
 PK/PD  
  Clinical efficacy 
 Specific safety 
 Immunogenicity 
 Pharmacovigilance 
 
Since the quality, control of biopharmaceutical products has a great prospect in terms of the 
safe access to treatment that patients need. The quality of them must comply with relevant 
internationally accepted criteria. Quality in biopharmaceutical products is a broad concept 
covering all aspects that affect the efficacy and safety of these products. All of the measures 
that require the assurance of biopharmaceutical quality constitute the quality assurance 
system. The Quality Assurance system consists of Quality Management-QM, Quality 
Assurance-QA and Good Manufacturing Practices-GMP and Quality Control-QC. As quality 
control and analysis of biopharmaceutical products are a part of GMP, quality control 
analyses should be carried out using validated methods appropriately to ensure the quality of 
the product. Biopharmaceutical products are subjected to quality control criteria and analysis 
within the scope of internationally accepted standards and guidelines specified or guided, 
including formulation, place and form of use. The quality control analyses made in 
biopharmaceutical products are mentioned below in the general framework within the scope 
of biopharmaceutical forms. 
 
Biological/biotechnological product analysis in pharmacopieas can be grouped as below and 
can be given in detail in Table 1 (5-8); 
• Biological activity by cell culture method, 
• Qualification and quantification byThe Enzyme-Linked Immunosorbent Assay-
ELISA and High Performance Liquid Chromatography-HPLC methods, 
• Total and free polyribosylribitol phosphate-PRP quantification with Isoelectric 
Focusing-IEF, Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis-SDS 
PAGE, Western Blotting methods, 
• In vivo Potency Test, 
• In vivo Biological Reactivity Test, 
• Physical tests: Physical controls, pH determination, total and bound protein, protein 
nitrogen, phenol, thimerosal, free formaldehyde, aluminium, humidity, residual 
humidity, phosphorus, PRP, sucrose, cresol, tween 80, glycine, ovalbumin, o-acetyl 
NaCl (salt) and volume, 
• Sterility test (membrane filtration method), 
• Limulus Amebocyte Lysate-LAL test, 
• Pyrogen test. 
 
 
Table 1. Pharmacopoeial methods for quality control of biopharmaceuticals. 
 Spesification Measurement 
General Tests pH Calibrated pH meter 
Identitiy and 
Heterogeneity 
Dissolved molecule 
concentration 
Osmolality 
Charge paternity Ion-Exchange Chromatography 
 Molecule weight   
Primer structure   
High level structure Nuclear Magnetic Rezonanse-NMR, 
circular dichroism 
Glycolysation 
heterogeneity 
Gas Chromatography/monosaccharide 
structure analysis with Mass 
Spectrometry, oligosaccharide analysis 
Amino terminal 
determination of protein 
N terminal sequencing and HPLC 
Carboxy terminal 
determination of protein 
C-terminal sequencing with a 
combination of peptide mapping and 
electrospray ionization-mass 
spectrometry / mass spectrometry 
Purity and  
Impurities 
Fragments and isoforms SDS-PAGE (reduced and non-reduced) 
HPLC, ultra-HPLC, liquid 
chromatography / mass spectrometry 
Deamidation products IEF, Ion exchange chromatography, 
peptide mapping 
Dimers and large 
aggregates 
Size exclusion chromatography, 
ultracentrifuge, SDS PAGE 
Post-translational 
modifications 
Peptide mapping, Liquid 
Chromatography-Electrospray Ionization 
/ Mass Spectrometry 
Host Cell proteins SDS PAGE, immunological tests 
Related proteins SDS PAGE, immunological tests, HPLC, 
liquid chromatography/ mass 
spectrometry 
Production-based 
impurities 
Gas chromatography/ mass spectrometry 
Potens Validated biological 
potency tests 
Potens  
Quantity Protein content UV scanning  
 
 
It is critical to prove that biopharmaceutical products are continuously produced at the 
desired quality and meet the specified specifications to ensure effective and safe treatment. 
Therefore, all quality control analyses of the starting materials to the finished product are 
required as part of GMP. Which analyses are to be made for which biopharmaceutical 
product is determined according to the guidelines of the International Council for 
Harmonization of Technical Requirements for Pharmaceuticals for Human Use. With the 
developments in the pharmaceutical field, quality control tests will also diversify in parallel 
 with newly developed innovative products and devices in addition to the mentioned analysis 
methods. For example; coulometric moisture determination with Karl Fischer method, 
particle size distribution and thermal analyses (Thermogravimetric Analysis-TGA, 
Differential Scanning Calorimetry-DSC) draws attention among the new tests that may be 
included in this variety. 
 
CONCLUSION 
Biosimilar products are gaining importance day by day, and there are many draft legislation 
and guidelines prepared by legal authorities for these products. In this direction, it will be 
useful to follow scientific and technological developments and current legislation during 
R&D, manufacturing and quality control stages. 
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